This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Conceptus® Reports Second Quarter Sales Of $36.8 Million

Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure (R) procedure, the first proven non-surgical permanent birth control method available, today reported financial results for the three months ended June 30, 2010.

Net sales for the second quarter of 2010 were $36.8 million, an increase of 11.5% over net sales of $33.0 million for the second quarter of 2009. Net sales were within the Company’s revised guidance of $36.8 million to $36.9 million issued in July of this year, but were below the Company’s original guidance of $39.5 million to $41.0 million issued in April of 2010.

The Company reported a net loss for the second quarter of 2010 of $0.3 million, or ($0.01) per share, compared with a net loss in the same period of 2009 of $0.6 million, or ($0.02) per share. These results were consistent with the Company’s revised net loss guidance of ($0.02) to ($0.01) per share, although below the Company’s original guidance of $0.00 to $0.03 per diluted share issued in April of 2010. Non-GAAP net income for the second quarter of 2010 was $3.5 million, or $0.11 per diluted share, compared with non-GAAP net income for the prior year second quarter of $2.4 million, or $0.08 per diluted share.

Compared with the prior year second quarter, domestic sales of the Essure system increased 7.4% to $28.0 million and international sales increased 26.5% to $8.9 million. Domestic sales growth reflects continued increases in both the number of physicians entering and completing training and in the number of certified physicians performing the Essure procedure in-office. During the second quarter of 2010, the Company entered approximately 400 physicians into preceptorship, certified approximately 330 physicians and transitioned approximately 160 physicians to performing procedures in the office setting. Approximately 11,750 physicians have performed at least one Essure procedure. Of total Essure-trained physicians, 44% are performing the Essure procedure in sites of minimal anesthesia, representing 66% of total procedure volume in the second quarter of 2010, which is consistent with the immediately preceding quarter and a 400 basis point increase over the prior year second quarter. International sales growth was negatively impacted by a stronger U.S. dollar in the current period compared with a year ago. International unit volume growth was 35% compared with the second quarter of 2009.

Gross profit for the second quarter of 2010 was $29.6 million, compared with $26.4 million for the second quarter of 2009. Gross profit margin was 80% of net sales for the second quarter of 2010, consistent with the second quarter of 2009. Sequential gross profit margin decreased slightly from 81% in the first quarter of 2010 and 82% in the fourth quarter of 2009, primarily due to a higher percentage of lower-margin international sales as well as the stronger U.S. dollar in the second quarter of 2010. Total operating expenses for the second quarter of 2010 were $28.1 million, up from $25.3 million for the second quarter of 2009, reflecting increased spending on field sales, consumer marketing and legal fees.

1 of 6

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs